Dewaraja Lab

Research focus

NIH R01 · 2024

Enhancing radioligand therapy for prostate cancer with biomarker and dosimetry guided personalization

ABSTRACT Radiopharmaceutical therapy (RPT) that delivers targeted cytotoxic radiation to cancer cells is typically administered on a fixed activity basis, without personalization, in stark contrast to external beam radiotherapy. 177Lu-labelled prostate-specific membrane antigen (PSMA) targeted radioligand therapy (RLT) is a promising RPT for metastatic castrate resistant prostate cancer (mCRPC) that was recently FDA approved as a fixed activity treatment (7.4 GBq/cycle delivered over 6 cycles). This standardized approach fails to take advantage of unique properties inherent to 177Lu: in addition to therapeutic beta particles, 177Lu emits gamma-rays imageable by SPECT, allowing precise…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.